arrow
R

Rafael López Castro

Hospital Clínico Universitario de Valladolid
H指数:21
被引数:2,351

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Primary Melanoma Stage as a Predictor of Survival in Advanced Disease: Findings from the Spanish Melanoma Registry GEM1801

原发性黑色素瘤分期作为晚期疾病预后的预测因子:西班牙黑色素瘤登记研究GEM1801的结果

2026-10-050
PRE
Characteristics and clinical outcomes of a nationwide cohort of patients with small cell lung cancer following first-line treatment: Real-world evidence

小细胞肺癌患者一线治疗后全国队列的特点与临床结局:真实世界证据

2026-05-270
PRE
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

标题:西班牙免疫治疗和靶向治疗时代未知原发灶黑色素瘤的特征:前瞻性真实世界研究GEM 1801的结果

2025-12-200
PRE
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study

西班牙晚期黏膜黑色素瘤患者的治疗效果:来自真实世界GEM1801研究的结果

2025-12-010
PRE
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

应答率和长期生存率在晚期黑色素瘤患者中的表现:来自前瞻性队列研究gem-1801的数据

2025-11-280
OAAI
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement

多学科方法治疗早期和局部晚期非小细胞肺癌(NSCLC)患者:西班牙肺癌组(GECP)第二届专家共识声明

2025-09-300
PRE
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

度伐利尤单抗联合铂类-依托泊苷在广泛期小细胞肺癌一线治疗中的应用(CANTABRICO):一项单臂临床试验

2025-09-240
PRE
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

肢端黑色素瘤患者中基于抗PD-1抗体免疫疗法的效果不佳:西班牙黑色素瘤组(GEM)登记研究的结果

2025-08-210
PRE
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain

肺癌幸存者中第二原发癌的发病率:按肿瘤学治疗的西班牙全国前瞻性队列研究

2025-08-120
OA
Biomarker landscape in advanced NSCLC: insights from a national prospective registry

晚期NSCLC中的生物标志物图谱:一项全国性前瞻性注册研究的见解

2025-07-280
PRE
KRAS Mutation Status in NSCLC: Distribution across Occupational Categories

KRAS突变状态在非小细胞肺癌中的分布:职业类别的分布

CHEST
IF8.6
2025-07-150
PRE
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)

驱动基因致癌突变在非小细胞肺癌中的频率及欧洲室内氡暴露的估计(RADON EUROPE研究)

2025-06-260
OA
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study

使用NGS对晚期NSCLC进行全面的分子分型:ATLAS研究中可靶向突变的发生率及临床试验机会

2025-06-010
OAAI
Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial
2025-02-260
OAAI
Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry
2024-10-010
OAAI
Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study

西班牙肺癌患者室内氡水平:MIRROR研究的初步数据

2024-09-010
PRE